BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioMarin excels in Q4 with record revenues and gene therapy launch

BioMarin Pharmaceutical reported strong financial results in Q4 2022, achieving revenue growth, profitability, and successful introduction of the ROCTAVIAN gene therapy for hemophilia A.
The company's performance highlights its R&D capabilities, market positioning, and strategic readiness for upcoming product launches, positioning BioMarin for continued growth and innovation.
While facing challenges in reimbursement processes and regulatory requirements, BioMarin has opportunities to drive revenue expansion, market penetration, and address unmet medical needs through its innovative pipeline.

BioMarin reports strong Q1 earnings, eyes blockbuster status for ROCTAVIAN

BioMarin Pharmaceuticals had a robust Q1 2023, focusing on revenue growth, profitability, and commercial readiness for key drug launches. While facing challenges in Germany, the company is optimistic about the potential of ROCTAVIAN and VOXZOGO in driving future growth.

BioMarin excels in Q2 with record revenues and treatment milestones

BioMarin's strong Q2 performance, driven by record revenues and product demand, positions the company for growth.
Challenges like supply issues and site readiness are being addressed, while opportunities in new programs and markets are promising.
Overall, BioMarin's focus on compliance, expansion, and pipeline development sets a positive trajectory for future success.

BioMarin reports strong Q3 revenue growth, eyes Roctavian expansion

BioMarin's Q3 performance showed revenue growth driven by Voxzogo, with strong expectations for 2024 revenue.
New CEO Alexander Hardy is set to continue the core strategy, focusing on Roctavian's global launch and Voxzogo's growth potential.
Challenges include delays in Roctavian's takeoff and supply constraints for Voxzogo, but efforts are underway to address these issues.
Opportunities lie in Roctavian's revenue contribution, Voxzogo's U.S. growth potential, and leveraging CNP for stature improvements.

BioMarin posts robust Q4 earnings, eyes expansion in gene therapy

BioMarin Pharmaceutical delivered strong financial results in Q4 2023, driven by revenue growth and increased earnings per share. The company's focus on high-impact medicines and gene therapy expertise positions it well for future growth.
While facing challenges related to analyst inquiries and market adoption of key products like Roctavian and Voxzogo, BioMarin remains committed to innovation and optimizing its business model.
Opportunities lie in expanding product reach, maximizing shareholder value through strategic capital allocation, and driving innovation in transformative programs. BioMarin's long-term strategy and growth potential remain promising.

BioMarin reports record revenue, focuses on key assets for growth

BioMarin Pharmaceutical's Q1 2024 performance reflects strong revenue growth and financial stability, driven by key product demand.
While facing challenges such as revenue impact and supply constraints, the company's strategic focus on key assets and cost reduction initiatives bode well for future growth.
Opportunities lie in expanding Voxzogo's market reach, optimizing manufacturing capabilities, and maintaining a competitive edge in innovative treatments.

BioMarin Pharmaceuticals reports record revenue and profitability outlook for 2024

BioMarin Pharmaceuticals delivered strong financial performance in Q2 2024, driven by robust revenue growth and strategic decisions. The company's focus on profitability, expansion of key treatments, and progress in R&D highlight a promising outlook. Addressing analyst inquiries and leveraging upcoming events can further enhance investor confidence and market positioning.

BioMarin reports record Q3 revenues, eyes long-term growth targets

BioMarin Pharmaceuticals showcased robust financial performance and raised full-year guidance.
The company remains optimistic about its long-term growth prospects and is committed to defending its IP.
Strategic focus on expanding global reach and driving growth in enzyme therapies portfolio.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced an update to its previously reported results from Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A. Data will be shared at the International Society on Thrombosis and Haemostasis 2021 Virtual Congress to be held in July.

Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit

SAN RAFAEL, Calif., May 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results from an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A.

BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A

SAN RAFAEL, Calif., May 12, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral and three poster presentations on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A at the American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting being held May 11-14.

BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting

BioMarin (BMRN) beats estimates for both earnings and revenues in the first quarter of 2021.

BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision

BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q1 2021 Results - Earnings Call Transcript

BioMarin (BMRN) delivered earnings and revenue surprises of 75.00% and 9.11%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings and Revenue Estimates

Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 79.55% over the past year to $0.09, which beat the estimate of ($0.10).

Biomarin Pharmaceutical: Q1 Earnings Insights

SAN RAFAEL, Calif., April 29, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2021 2020 % Change Total Revenues $ 486.0 $ 502.1 (3) % Net Product Revenues Marketed by BioMarin (1) $ 417.8 $ 433.3 (4) % Vimizim Net Product Revenues $ 158.4 $ 137.2 15 % Naglazyme Net Product Revenues $ 107.3 $ 114.3 (6) % Kuvan Net Product Revenues $ 70.8 $ 122.0 (42) % Palynziq Net Product Revenues $ 54.0 $ 34.6 56 % Brineura Net Product Revenues $ 27.3 $ 24.0 14 % Aldurazyme Net Product Revenues $ 50.0 $ 55.7 (10) % GAAP Net Income $ 17.4 $ 81.4 GAAP Net Income per Share – Basic $ 0.10 $ 0.45 GAAP Net Income per Share – Diluted $ 0.09 $ 0.44 Non-GAAP Income (2) $ 104.4 $ 116.5   March 31, 2021 December 31, 2020 Cash, cash equivalents and investments $ 1,408.6 $ 1,350.9 (1) Net Product Revenues Marketed by BioMarin is the sum of revenues from Vimizim, Kuvan, Naglazyme, Palynziq, Brineura and Firdapse, each calculated in accordance with Generally Accepted Accounting Principles in the United States (U.S. GAAP).

BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates

SEATTLE and SAN RAFAEL, Calif., April 28, 2021 /PRNewswire/ -- The Allen Institute and BioMarin Pharmaceutical Inc. announced a collaboration today that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic diseases of the central nervous system.

Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases

Alexion Pharma

Activision Blizzard

Baker Hughes Co

Esperion Therapeutics

Fate Therapeutics

Flexion Therapeutics

Reata Pharmaceuticals

With the trading day about halfway over, each of the major averages had notched a solid gain and was holding just below its respective all-time high.

Alexion, Activision, Baker Hughes and More Monday Afternoon Analyst Calls

SAN RAFAEL, Calif., April 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) presented new and updated data at the 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting that demonstrates the Company's ongoing commitment to understanding the lifetime impact of achondroplasia and the potential of an investigational treatment choice to address the root cause of achondroplasia.

BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice

SAN RAFAEL, Calif., April 13, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 29, at 4:30 p.m.

BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound?

SAN RAFAEL, Calif., March 20, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine Society's Annual Meeting by Professor Ravi Savarirayan, M.B.

BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide

BMRN's core business value is around $78 per share. Even with conservative assumptions, ValRox represents a significant commercial opportunity.

BioMarin: One Step Back Before The Jump

argenx

Biohaven Pharmaceutical Hld

Mirati Therapeutics

Novo Nordisk

Novartis

Pharmaceutical stocks are a sector with unique success factors. One factor is developing blockbuster drugs.

7 Pharmaceutical Stocks Working on Their Next Blockbuster

FDA grants RMAT designation to BioMarin's (BMRN) gene therapy for severe hemophilia A, valoctocogene roxaparvovec, after rejecting it last year.

BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) valoctocogene roxaparvovec investigational gene therapy for the treatment of adults with severe hemophilia A.  RMAT is an expedited program intended to facilitate the development and review of regenerative medicine therapies.

BioMarin's Hemophilia Gene Therapy Scores RMAT Designation In US

General Electric

Anthem

American Outdoor Brands

American Water Works

CRISPR Therapeutics

Charles Schwab

Wheaton Precious Metals

Yext

With the trading day about halfway over, the broad markets had managed to push higher on the day, despite dipping into the red earlier.

Anthem, BioMarin, CRISPR, GE and More Thursday Afternoon Analyst Calls

SAN RAFAEL, Calif., March 3, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has completed full enrollment in a global Phase 2 randomized, placebo-controlled study of vosoritide, an investigational, once daily injection analog of C-type...

BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

Biomarin Pharmaceutical (NASDAQ:BMRN) is currently down 7.49% to a price of $78.33. Friday the stock has been traded at a volume of 86.17 thousand, about 7.66% of its recent 30-day volume average of 1.13 million.

Why Biomarin Pharmaceutical's Stock is Down During Today's Session

BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.

BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull

BioMarin Pharmaceutical's (BMRN) CEO J.J. Bienaime on Q4 2020 Results - Earnings Call Transcript

Biomarin Pharmaceutical (NASDAQ:BMRN) unveils its next round of earnings this Thursday, February 25. Get prepared with Benzinga's ultimate preview for Biomarin Pharmaceutical's Q4 earnings.

Biomarin Pharmaceutical's Earnings Outlook

SAN RAFAEL, Calif., Feb. 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of former Goldman Sachs partner and executive in the life sciences industry, Maykin Ho, Ph.D., to...

News for BioMarin Pharmaceutical Stock (BMRN)